Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Molecular subtyping of breast cancer improves identification of both high and low risk patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. eHealth-mind the gap

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Transcriptome analysis enables classification of breast tumors into molecular subtypes that correlate with prognosis and effect of therapy. We evaluated the clinical benefits of molecular subtyping compared to our current diagnostic practice.

MATERIALS AND METHODS: Molecular subtyping was performed on a consecutive and unselected series of 524 tumors from women with primary breast cancer (n = 508). Tumors were classified by the 256 gene expression signature (CIT) and compared to conventional immunohistochemistry (IHC) procedures.

RESULTS: More than 99% of tumors were eligible for molecular classification and final reports were available prior to the multidisciplinary conference. Using a prognostic standard mortality rate index (PSMRi) developed by the Danish Breast Cancer Group (DBCG) 39 patients were assigned with an intermediate risk and among these 16 (41%) were furthermore diagnosed by the multi-gene signature assigned with a luminal A tumor and consequently spared adjuvant chemotherapy. There was overall agreement between mRNA derived and IHC hormone receptor status, whereas IHC Ki67 protein proliferative index proved inaccurate, compared to the mRNA derived index. Forty-one patients with basal-like (basL) subtypes were screened for predisposing mutations regardless of clinical predisposition. Of those 17% carried pathogenic mutations.

CONCLUSION: Transcriptome based subtyping of breast tumors evidently reduces the need for adjuvant chemotherapy and improves identification of women with predisposing mutations. The results imply that transcriptome profiling should become an integrated part of current breast cancer management.

Original languageEnglish
JournalActa oncologica
Volume57
Issue number1
Pages (from-to)58-66
ISSN0284-186X
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52152702